[HTML][HTML] The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …
being rolled out under emergency use authorizations. It is of great concern that newly …
A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection
Broadly neutralizing antibodies (bnAbs) to coronaviruses (CoVs) are valuable in their own
right as prophylactic and therapeutic reagents to treat diverse CoVs and as templates for …
right as prophylactic and therapeutic reagents to treat diverse CoVs and as templates for …
Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody
Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to
reduce the burden placed on health systems, the situation remains critical. Effective …
reduce the burden placed on health systems, the situation remains critical. Effective …
Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19
MJ Levin, A Ustianowski, S De Wit… - … England Journal of …, 2022 - Mass Medical Soc
Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
X Chi, R Yan, J Zhang, G Zhang, Y Zhang, M Hao… - Science, 2020 - science.org
Developing therapeutics against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) could be guided by the distribution of epitopes, not only on the receptor binding …
CoV-2) could be guided by the distribution of epitopes, not only on the receptor binding …
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
Convergent evolution in SARS-CoV-2 spike creates a variant soup from which new COVID-19 waves emerge
The first 2 years of the COVID-19 pandemic were mainly characterized by recurrent
mutations of SARS-CoV-2 Spike protein at residues K417, L452, E484, N501 and P681 …
mutations of SARS-CoV-2 Spike protein at residues K417, L452, E484, N501 and P681 …
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
T Noy-Porat, E Makdasi, R Alcalay, A Mechaly… - Nature …, 2020 - nature.com
The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …
Sequential analysis of binding and neutralizing antibody in COVID-19 convalescent patients at 14 months after SARS-CoV-2 infection
M Rosati, E Terpos, I Ntanasis-Stathopoulos… - Frontiers in …, 2021 - frontiersin.org
Durability of SARS-CoV-2 Spike antibody responses after infection provides information
relevant to understanding protection against COVID-19 in humans. We report the results of a …
relevant to understanding protection against COVID-19 in humans. We report the results of a …